Physician profile
Danny Woo
NPI 1639272057
$4,307.14
in general payments reported to CMS, 2019-2025
26 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,141 · 2020: $571 · 2022: $142 · 2023: $166 · 2024: $154 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $453.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $597.47 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $475.40 | 2019-2024 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals Lp | $445.65 | 2019-2025 | Farxiga, Brilinta |
| Sanofi-Aventis U.S. LLC | $338.29 | 2019 | |
| Janssen Pharmaceuticals, INC | $332.69 | 2019-2020 | |
| Boston Scientific Corporation | $280.99 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $248.72 | 2019-2025 | Lifevest |
| Pfizer INC. | $235.49 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.47 | 2019-2020 | |
| Medtronic Vascular, INC. | $180.41 | 2019 | |
| Novartis Pharmaceuticals Corporation | $165.77 | 2019-2020 | |
| Abbott Laboratories | $147.38 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $108.19 | 2019-2020 | |
| Gilead Sciences, INC. | $89.03 | 2019-2020 | |
| Amarin Pharma, INC. | $72.63 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $61.96 | 2019 | |
| Edwards Lifesciences Corporation | $51.68 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $51.50 | 2019-2020 | |
| Novo Nordisk INC | $47.77 | 2025 | Ozempic, Wegovy |
| Regeneron Healthcare Solutions, INC. | $39.68 | 2019 | |
| Bridgebio Pharma, INC. | $25.00 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $21.94 | 2020 | |
| Philips North America LLC | $20.49 | 2022 | |
| Braemar Manufacturing, LLC | $16.39 | 2019 | |
| Portola Pharmaceuticals, LLC | $15.90 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Woo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.